Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Acquires 10,000 Shares of Stock

Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average price of $2.67 per share, with a total value of $26,700.00. Following the acquisition, the director owned 225,707 shares of the company’s stock, valued at $602,637.69. This represents a 4.64% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Organogenesis Trading Up 0.2%

NASDAQ:ORGO traded up $0.01 during trading hours on Thursday, hitting $2.68. The company had a trading volume of 220,886 shares, compared to its average volume of 735,988. The company has a market capitalization of $344.11 million, a PE ratio of 33.44 and a beta of 1.43. The stock has a 50-day moving average price of $3.79 and a 200 day moving average price of $4.48. Organogenesis has a 52 week low of $2.61 and a 52 week high of $7.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. The business had revenue of $225.61 million for the quarter, compared to the consensus estimate of $172.68 million. On average, equities research analysts predict that Organogenesis will post -0.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “buy” rating in a research note on Sunday. Weiss Ratings raised Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, February 27th. Finally, BTIG Research decreased their target price on Organogenesis from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Institutional Investors Weigh In On Organogenesis

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP bought a new position in shares of Organogenesis during the third quarter valued at $25,000. State of Alaska Department of Revenue purchased a new stake in Organogenesis during the 3rd quarter valued at about $25,000. Flagship Harbor Advisors LLC purchased a new stake in Organogenesis during the 4th quarter valued at about $34,000. Federated Hermes Inc. increased its stake in Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after purchasing an additional 2,953 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Organogenesis during the 4th quarter valued at about $57,000. 49.57% of the stock is owned by institutional investors.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.